

# SCIENTIFIC REPORTS

OPEN

## Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Xuejiao Song, Tiantao Gao, Ningyu Wang, Qiang Feng, Xinyu You, Tinghong Ye, Qian Lei, Yongxia Zhu, Menghua Xiong, Yong Xia, Fangfang Yang, Yaojie Shi, Yuquan Wei, Lidan Zhang & Luoting Yu

*Scientific Reports* 6:20864; doi: 10.1038/srep20864; published online 12 February 2016; updated 29 April 2016

This Article contains typographical errors.


In the Results section under subheading ‘Impact of ZLD1039 on breast cancer cell growth’,

“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with  $IC_{50}$  values of  $0.99 \pm 0.23$  and  $0.089 \pm 0.019 \mu\text{M}$ , respectively”.

should read:

“Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with  $IC_{50}$  values of  $0.99 \pm 0.23$  and  $1.089 \pm 0.019 \mu\text{M}$ , respectively”.

In Figure 3d, the x-axis ‘1–8 days of treatment’ was incorrectly given as ‘0–7 days of treatment’. The correct Figure 3d appears below as Fig. 1.



**Figure 1.**



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>